Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli
Antimicrobial Agents and Chemotherapy · 08.10.2024 · 68 (10)
DOI: 10.1128/aac.00693-24 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 08.10.2024. Verfasst von Lili Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, US…. Hauptthemen laut MEDLINE: Aztreonam, Azabicyclo Compounds, Microbial Sensitivity Tests, Anti-Bacterial Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Treatment options for carbapenem-resistant gram-negative bacilli (CR-GNB), especially metallo-β-lactamase (MBL)-producing CR-GNB, are limited. Aztreonam (ATM) in combination with avibactam (AVI) has shown potential for treating MBL-producing carbapenem-resistant Enterobacterales (CREs) and Stenotrophomonas maltophilia . However, data on ATM in combination with other β-lactamase inhibitors (BLIs) are limited. We performed a multicenter study to evaluate the in vitro activities of ATM in combination with AVI, vaborbactam (VAB), relebactam (REL), tazobactam (TAZ) as well as with their commercially available formulations against CREs and S. maltophilia using broth microdilution. AVI restored ATM activity for MBL-producing CREs (ATM: 9.8% vs ATM-AVI: 78.0%) and S. maltophilia (ATM: 0% vs ATM-AVI: 93.3%). REL also moderately restored activity of ATM in MBL-producing CREs (ATM: 9.8% vs ATM-REL: 42.7%) and S. maltophilia (ATM: 0% vs ATM-REL: 68.9%). VAB and TAZ demonstrated very limited effect on the activity of ATM against CR-GNB evaluated. The combination of ATM with ceftazidime-AVI (CAZ-AVI) demonstrated maximum activity against CREs. Although ATM-CAZ-AVI is the most potent regimen available for CREs and S. maltophilia , ATM-IMI-REL might be a reasonable alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Immunology, Division of Laboratory Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
- Department of Pathology, Division of Medical Microbiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Lili Tao, Harley Harris, Patricia J Simner, Romney Humphries
Zitieren
APA
Tao, L., Dahlquist, A., Harris, H., Jacobs, E., Wenzler, E., Simner, P. J., & Humphries, R. (2024). Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy, 68(10). https://doi.org/10.1128/aac.00693-24
Vancouver
Tao L, Dahlquist A, Harris H, Jacobs E, Wenzler E, Simner PJ, et al. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. Antimicrobial Agents and Chemotherapy. 2024;68(10). doi:10.1128/aac.00693-24
BibTeX
@article{Tao2024,
author = {Tao, Lili and Dahlquist, Ashley and Harris, Harley and Jacobs, Emily and Wenzler, Eric and Simner, Patricia J and Humphries, Romney},
title = {Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {10},
doi = {10.1128/aac.00693-24}
}
EUVIMED